文献速递血液净化与透析

成人血液透析随机试验报告结局的范围与一致性:系统综述

Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review.
PubMed 文献 · Am J Kidney Dis · 2018-02-21

该系统综述评估了血液透析临床试验报告结局的范围与一致性,纳入362项试验,提取10713个结局指标并归类至81个结局域。结果显示结局报告集中于替代指标,临床和患者报告结局少见,且结局域、指标、度量及时间点存在极端多重性和异质性,影响干预比较效益估计的可靠性。

要点

  • 透析试验结局报告以替代指标为主,临床和患者报告结局少见。
  • 结局域、指标、度量及时间点存在极端多重性和异质性。
  • 现有干预比较效益估计不可靠,结局报告改进不一致。

核心结论

  • 成人血液透析临床试验报告的结局集中于替代结局,而非临床和患者为中心的结局。
  • 结局在域、指标、度量及时间点各层面存在极端多重性和异质性,导致干预比较效益估计不可靠且改进不一致。

研究设计与样本

  • 系统综述,纳入2016年8月29日前发表的Cochrane系统综述中所有试验及2011年1月以来在ClinicalTrials.gov注册和发表的试验。
  • 共纳入362项试验,提取10713个结局指标,中位数每试验21个(IQR 10-39),归类至81个结局域。

主要发现

  • 81个结局域中,替代域42个(52%),临床域25个(31%),患者报告域14个(17%)。
  • 报告最多的5个域均为替代指标:磷酸盐(125项[35%])、透析充分性(120项[33%])、贫血(115项[32%])、炎症标志物(114项[31%])、钙(109项[30%])。
  • 死亡率、心血管疾病和生活质量报告频率很低:分别为73项(20%)、44项(12%)、32项(9%)。
  • 报告结局指标数量随时间显著变化。

临床怎么用

  • 解读透析试验证据时需注意结局以替代指标为主,临床和患者报告结局有限。
  • 关注结局指标的多重性和异质性对比较效益估计可靠性的影响。

局限性

  • 为可行性,仅纳入Cochrane系统综述或ClinicalTrials.gov识别的试验作为抽样框架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical trials are most informative for evidence-based decision making when they consistently measure and report outcomes of relevance to stakeholders. We aimed to assess the scope and consistency of outcomes reported in trials for hemodialysis. STUDY DESIGN: Systematic review. SETTING & POPULATION: Adults requiring maintenance hemodialysis enrolled in clinical trials. SELECTION CRITERIA: All Cochrane systematic reviews of interventions published by August 29, 2016, and the trials published and registered in ClinicalTrials.gov since January 2011. INTERVENTIONS: Any hemodialysis-related interventions. OUTCOMES: Frequency and characteristics of the reported outcome domains and measures. RESULTS: From the 362 trials, we extracted and classified 10,713 outcome measures (a median of 21 [IQR, 10-39] per trial) into 81 different outcome domains, of which 42 (52%) were surrogate; 25 (31%), clinical; and 14 (17%), patient reported. The number of outcome measures reported significantly changed over time. The 5 most commonly reported domains were all surrogates: phosphate (125 [35%] trials), dialysis adequacy (120 [33%]), anemia (115 [32%]), inflammatory markers (114 [31%]), and calcium (109 [30%]). Mortality, cardiovascular diseases, and quality of life were reported very infrequently (73 [20%], 44 [12%], and 32 [9%], respectively). LIMITATIONS: For feasibility, we included a sampling frame that included only trials identified in Cochrane systematic reviews or ClinicalTrials.gov. CONCLUSIONS: Outcomes reported in clinical trials involving adults receiving hemodialysis are focused on surrogate outcomes, rather than clinical and patient-centered outcomes. There is also extreme multiplicity and heterogeneity at every level: domain, measure, metric, and time point. Estimates of the comparative effectiveness of available interventions are unreliable and improvements over time have been inconsistent.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Sautenet B, Tong A, Williams G, et al. Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review. Am J Kidney Dis. 2018. PMID: 29475768. doi:10.1053/j.ajkd.2017.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。